Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

Ipsen

Status: Completed

Conditions: Hepatocellular Carcinoma; Renal Cell Carcinoma; Differentiated Thyroid Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03776123

A-KR-60000-021

Details and patient eligibility

About

The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.

Enrollment: 347 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who meet 'Indications' of label for Cabometyx™ as monotherapy
• Patients who are treated with Cabometyx™ for the first time according to label for Cabometyx™ as monotherapy
• Patients who are aged 18 years or older
• Patients who are willing to provide written consent after being informed of this surveillance

Exclusion criteria

• Patients who are contraindicated for Cabometyx™ based on Cabometyx™ label